NCT03890744View on ClinicalTrials.gov

ModraDoc006/r in Patients With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

February 13, 2020

Study Completion Date

November 9, 2020

Conditions
Metastatic Breast CancerRecurrent Breast Cancer
Interventions
DRUG

ModraDoc006/r

Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets

Trial Locations (4)

4000

Centre Hospitalier Universitaire de Liège, Liège

5000

Odense University Hospital, Odense

B-1000

Institut Jules Bordet, Brussels

Unknown

Hospital Quiron Pozuelo, Madrid

Sponsors
All Listed Sponsors
lead

Modra Pharmaceuticals

INDUSTRY

NCT03890744 - ModraDoc006/r in Patients With Breast Cancer | Biotech Hunter | Biotech Hunter